Sun Pharmaceutical announced to buy GlaxoSmithKline's opiates business in Australia

Mar 4, 2015 16:45 IST

Dilip Shanghvi led Sun Pharmaceutical Industries Ltd on 3 March 2015 announced to buy GlaxoSmithKline's opiates business in Australia.

As per the deal, GSK's opiate facilities in Latrobe in Tasmania) and Port Fairy in Victoria will be transferred to a subsidiary of Sun Pharma along with GSK’s portfolio of opiates products along with inventory.

However, Sun Pharma will retain the staff at both the facilities.

The acquisition is part of the Sun Pharma's plan to improve its presence in the pain management segment and GSK's plan to exit the non-core business, that is, it will allow GSK to focus its innovative products that will be central to the company's growth strategy in Australia.

Poppy industry of Australia is the world's largest legal supplier of pharmaceutical grade opiates for painkillers.

GSK is one of three firms that control the crop and production in Tasmania and supplies a quarter of the world's medicinal opiate needs from poppies grown by farmers in Tasmania.

Is this article important for exams ? Yes13 People Agreed
Read more Current Affairs on: Sun Pharmaceutical , GlaxoSmithKline , opiates business , Australia

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK